论文部分内容阅读
尾加压素II(urotensinII,UII)是迄今所知的体内最强的缩血管肽 ,它除了具有收缩 /舒张血管、心肌变力等生物学效应外 ,对血管平滑肌细胞、心成纤维细胞、肿瘤细胞等多种细胞具有明显的促细胞增殖效应 ,该作用主要通过Ca2 + 及Ca2 + 依赖的CaN通路、PKC通路、MAPK通路。UII还能通过PKC Src酪氨酸激酶 MAPK途径与中度氧化LDL、5 羟色胺、溶血卵磷脂等物质发挥协同促细胞增殖作用。UII的单独和协同促增殖作用很可能对阐明细胞增殖机制有重要补充 ,尤其是 ,UII及其受体在心血管含量丰富 ,高血压、动脉粥样硬化、心衰等心血管疾病患者血浆UII含量升高 ,UII很可能是这些疾病促心血管细胞增殖的重要因子。
Urotensin II (UII) is the strongest vasoperitoneal peptide in the body known to date. In addition to its biological effects of contracting / relaxing blood vessels and myocardial degeneration, vascular endothelial cells such as vascular smooth muscle cells, cardiac fibroblasts, Tumor cells and other cells have obvious cell proliferation effects, mainly through the Ca2 + and Ca2-dependent CaN pathway, PKC pathway, MAPK pathway. UII can synergize the cell proliferation by PKC Src tyrosine kinase MAPK pathway and moderate oxidation of LDL, serotonin, lysolecithin and other substances. UII alone and synergistically promote proliferation is likely to elucidate the mechanism of cell proliferation important complement, in particular, UII and its receptors in cardiovascular rich, high blood pressure, atherosclerosis, heart failure and other cardiovascular disease in patients with plasma UII content UII is likely to be an important factor in these diseases to promote the proliferation of cardiovascular cells.